Nuformix plc (LON:NFX – Get Free Report) shares dropped 11.9% during trading on Tuesday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 14,879,378 shares traded hands during trading, an increase of 182% from the average daily volume of 5,271,314 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Trading Down 11.9 %
The business has a 50-day moving average of GBX 0.16 and a 200 day moving average of GBX 0.18. The stock has a market cap of £426,041.20, a PE ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Articles
- Five stocks we like better than Nuformix
- Upcoming IPO Stock Lockup Period, Explained
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- What is a Secondary Public Offering? What Investors Need to Know
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
